The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: A systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Sheng, Jin ^a,b   Yang, Yunpeng ^a,b   Ma, Yuxiang ^a,b   Yang, Bijun ^c   Zhang, Yaxiong ^c   Kang, Shiyang ^c   Zhou, Ting ^a,b   Hong, Shaodong ^a,b   Qin, Tao ^a,b   Hu, Zhihuang ^a,b   Fang, Wenfeng ^a,b   Huang, Yan ^a,b   Zhang, Li ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Colorectal Surgery   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CYTOTOXIC AGENT; DOCETAXEL; ERLOTINIB; MONOCLONAL ANTIBODY; NINTEDANIB; PAZOPANIB; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; VANDETANIB; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; DATA BASE; DRUG CHOICE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HISTOPATHOLOGY; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84934936604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127306     Document Type: Review

References (35)

1. Li T, Kung HJ, Mack PC, Gandara DR (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31: 1039-1049. doi: 10.1200/JCO.2012.45.3753 PMID: 23401433
2. Leighl NB (2012) Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol 19: S52-S58. doi: 10.3747/co.19.1114 PMID: 22787411
3. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. (2012) Non-small cell lung cancer. J Natl Compr Canc Netw 10: 1236-1271. PMID: 23054877
4. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103. PMID: 10811675
5. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132. PMID: 16014882
6. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597. PMID: 15117980
7. Hotta K, Fujiwara Y, Kiura K, Takigawa N, Tabata M, Ueoka H, et al. (2007) Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol 2: 402-407. PMID: 17473655
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550. PMID: 17167137
9. Lima AB, Macedo LT, Sasse AD (2011) Addition of bevacizumab to chemotherapy in advanced nonsmall cell lung cancer: a systematic review and meta-analysis. PLoS One 6: e22681. doi: 10.1371/journal.pone.0022681 PMID: 21829644
10. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. (2013) Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24: 20-30. doi: 10.1093/annonc/mds590 PMID: 23180113
11. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3: i27-i39.
12. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 3.2015), 2015. Available: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17: 1-12. PMID: 8721797
14. Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9: 214-221. doi: 10.1097/JTO.0000000000000071 PMID: 24419419
15. Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn M-J, Tiangco B, et al. (2013) Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 31, (suppl; abstr 8034)
16. de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, et al. (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, doubleblind phase III trial. J Clin Oncol 29: 1067-1074. doi: 10.1200/JCO.2010.29.5717 PMID: 21282537
17. Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, et al. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619-626. doi: 10.1016/S1470-2045(10)70132-7 PMID: 20570559
18. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, et al. (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25: 4270-4277. PMID: 17878479
19. Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, et al. (2012) Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 30: 3640-3647. doi: 10.1200/JCO.2012.42.6932 PMID: 22965962
20. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384: 665-673. doi: 10.1016/S0140-6736(14)60845-X PMID: 24933332
21. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15: 143-155. doi: 10.1016/S1470-2045(13)70586-2 PMID: 24411639
22. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, et al. (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377: 1846-1854. doi: 10.1016/S0140-6736(11)60545-X PMID: 21621716
23. Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, et al. (2013) A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol 24: 2382-2389. doi: 10.1093/annonc/mdt212 PMID: 23788751
24. Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, et al. (2012) Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 30: 2070-2078. doi: 10.1200/JCO.2011.39.2993 PMID: 22564989
25. Spigel DR, Burris HR, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, et al. (2011) Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 29: 2582-2589. doi: 10.1200/JCO.2010.30.7678 PMID: 21576636
26. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25: 4743-4750. PMID: 17909199
27. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous nonsmall-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804-1809. doi: 10.1093/annonc/mdq020 PMID: 20150572
28. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346. PMID: 12907602
29. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313: 1785-1787. PMID: 16990548
30. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273. doi: 10.1016/j.ccr.2008.08.001 PMID: 18772115
31. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. (2009) The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol 4: 1568-1571. doi: 10.1097/JTO.0b013e3181c06980 PMID: 20009911
32. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957. doi: 10.1056/NEJMoa0810699 PMID: 19692680
33. Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, et al. (2013) Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 19: 3681-3692. doi: 10.1158/1078-0432.CCR-12-3635 PMID: 23685835
34. Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, et al. (2014) A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015). J Thorac Oncol 9: 848-855. doi: 10.1097/JTO.0000000000000160 PMID: 24807156
35. Bass MB, Yao B, Hei YJ, Ye Y, Davis GJ, Davis MT, et al. (2014) Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience. PLoS One 9: e108048. doi: 10.1371/journal.pone.0108048 PMID: 25314641